Canadian CANNAINVESTOR Magazine December 2018 | Page 38

We are not focused on growing the plant, which is quickly becoming a commodity, but instead our focus is on our unique service model that supplies our specific and committed customer base that is particularly vulnerable to chronic pain and opioid use and abuse. We have invested heavily into our operations and quality assurance departments to ensure every product that enters and leaves our facility upholds the highest Starseed standards.

You do a lot of work with employers, insurers and plan sponsors. Recently, Reformulary Group, who is a large independent drug plan company, signed you on. You are only one of three, good company I must say, joining MedReleaf and Aphria. How has that deal progressed since it was signed back on September 12th?

We are very excited about what’s to come with Reforumulary Group. The Reformulary Cannabis Standard is very consistent and aligned with our core strategy of supporting employers and employees to navigate the complex process of delivering medical cannabis as a paid benefit.

Similar topic…you’ve also signed an agreement to supply Shoppers Drug Mart with medical cannabis, joining a short list of great cannabis companies. This was expected to launch this fall, as part of Manulife Financial Corporations’ medical marijuana program. Can you update our readers on the status of this agreement? Is it up and operational yet?

We are very excited to be one of the eight licensed producers available for purchase on the Shoppers Drug Mart e-commerce site. This agreement will be operational once Shoppers Drug Mart obtains their sales license, which we hope will be very soon. Upon launch, medical professionals will have the opportunity to prescribe any of Starseed’s products across our Blue Star or Green Star lines to their patients.

Earlier this year you launched a unique medical cannabis supply and service model with LiUNA local 625 in Windsor, Ontario and expanding this across Canada as the ultimate intent. Can you elaborate on what this agreement is pertaining to, and the uniqueness of it?

38